MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, whilst one of sev... https://griffinibtld.glifeblog.com/30189026/details-fiction-and-parp-1-in-3